Kulicke & Soffa Q3 FY26 revenue surges to $330M, EPS $1.07, pointing to accelerating advanced packaging wins.

What happened

Kulicke & Soffa delivered a blowout Q3 FY26 with $330.4 million in revenue and non-GAAP EPS of $1.20, far above the trajectory implied by earlier guidance and consensus. The surge suggests that the company’s thermocompression bonding (TCB) and advanced packaging platforms are gaining significant traction with AI and HBM customers, translating design wins into revenue. Gross margins likely remained in the healthy mid-40s, driving net income of $57.4 million, a stark contrast to the losses of just a year ago. While one must watch for lumpiness in equipment shipments and China exposure, the scale of the beat indicates that the recovery and technology transition are well underway. This print materially de-risks the FY26 TCB revenue target of ~$100 million and strengthens the bull case.

Implication

Accelerating revenue and profitability suggest the advanced packaging thesis is playing out ahead of schedule, potentially driving FY26 revenue above $1B and justifying a higher valuation. However, the steep increase also raises the bar for sustained growth, and any slowdown in orders or margin pressure from competition could temper momentum. Investors should watch for segment-level disclosures to confirm TCB revenue breakout and gauge whether the growth is broad-based or lumpy. The balance sheet remains solid, but aggressive buybacks at higher prices could erode safety if the cycle turns. Overall, the risk/reward has improved, but the stock may already discount much of the good news, so adding on pullbacks is prudent.

Thesis delta

The Q3 results materially strengthen the bull case; the advanced packaging ramp is ahead of expectations, reducing downside risk from EA shutdown and China concentration. The rating could move from WAIT to ACCUMULATE if TCB revenue confirms $120M+ annual run rate, but we await confirmation of sustainability.